Project Number GC-201801-2014666 Agency/Funding Organization Alzheimer's Drug Discovery Foundation Funding Year 2018 View Full Project Details for ETHERAL : Epigenetic THERapy in ALzheimer’s Disease . A multicenter, multinational, randomized, double-blind, placebo-controlled, 3-arm, 26 weeks parallel-group study to evaluate the safety, tolerability of ORY-2001 in patients with mild-moderate AD Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 7. Early-stage Clinical Drug Development (Phase I and II Clinical Trials) q. Epigenetic Regulators Researcher and Organization Principal Investigator Bullock, Roger Principal Investigator First Name Roger Principal Investigator Last Name Bullock Awardee Organization Oryzon Genomics S.A. Contact PI Country Spain Project Detail Funding Opportunity Announcement Program to Accelerate Clinical Trials (PACT) RFP FY Overall Cost $1,500,000 Funding Organization Agency/Funding Organization Alzheimer's Drug Discovery Foundation Funding Organization Country United States
